COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,833 Articles (22,553 medRxiv, 8,280 bioRxiv)

Most recent first Previous |  Page 3022: Articles 30211-30220  | Next

An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 and multiple endemic, epidemic and bat coronavirus
Sheahan, T. P., Sims, A. C., Zhou, S., Hill, C., Leist, S. R., Schaefer, A., Agostini, M., Pruijssers, A., Brown, A. J., Bluemling, G., Natchus, M., Saindane, M., Kolykhalov, A., Painter, G., Swanstrom, R., Dinnon, K., Graham, R., Harcourt, J., Tamin, A., Thornburg, N. J., Montgomery, S. A., Chappell, J., Denison, M., Baric, R. S.
10.1101/2020.03.19.997890 — Posted: 2020-03-20 Discussion: Onsite
The first-in-class peptide binder to the SARS-CoV-2 spike protein
Zhang, G., Pomplun, S., Loftis, A. R., Loas, A., Pentelute, B. L.
10.1101/2020.03.19.999318 — Posted: 2020-03-20 Discussion: Onsite
High transmissibility of COVID-19 near symptom onset
Cheng, H.-Y., Jian, S.-W., Liu, D.-P., Ng, T.-C., Huang, W.-T., Taiwan COVID-19 outbreak investigation team, , Lin, H.-H.
10.1101/2020.03.18.20034561 — Posted: 2020-03-19
Forecasting of COVID-19 Confirmed Cases in Different Countries with ARIMA Models
Dehesh, T., Mardani-Fard, H. A., Dehesh, P.
10.1101/2020.03.13.20035345 — Posted: 2020-03-18
Is a 14-day quarantine period optimal for effectively controlling coronavirus disease 2019 (COVID-19)?
Jiang, X., Niu, Y., Li, X., Li, L., Cai, W., Chen, Y., Liao, B., Wang, E.
10.1101/2020.03.15.20036533 — Posted: 2020-03-18 Discussion: Onsite
Acute myelitis after SARS-CoV-2 infection: a case report.
Zhao, K., Huang, J., Dai, D., Feng, Y., Liu, L., Nie, S.
10.1101/2020.03.16.20035105 — Posted: 2020-03-18 Discussion: Offsite
Coronavirus disease-19: Summary of 2,370 Contact Investigations of the First 30 Cases in the Republic of Korea
Korea Centers for Disease Control and Prevention COVID-19 National Emergency Response Center, , Choe, Y. J.
10.1101/2020.03.15.20036350 — Posted: 2020-03-18
Coronavirus disease-19: The First 7,755 Cases in the Republic of Korea
COVID-19 National Emergency Response Center Korea Centers for Disease Control and Prevention, , Choe, Y. J.
10.1101/2020.03.15.20036368 — Posted: 2020-03-18
Stability of SARS-CoV-2 in different environmental conditions
Chin, A., Chu, J., Perera, M., Hui, K., Yen, H.-L., Chan, M., Peiris, M., Poon, L.
10.1101/2020.03.15.20036673 — Posted: 2020-03-18 Discussion: Onsite
A serological assay to detect SARS-CoV-2 seroconversion in humans
Amanat, F., Nguyen, T., Chromikova, V., Strohmeier, S., Stadlbauer, D., Javier, A., Jiang, K., Asthagiri-Arunkumar, G., Polanco, J., Bermudez-Gonzalez, M., Caplivski, D., Cheng, A., Kedzierska, K., Vapalahti, O., Hepojoki, J., Simon, V., Krammer, F.
10.1101/2020.03.17.20037713 — Posted: 2020-03-18 Discussion: Onsite | Offsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).